Catalyst OrthoScience

Overview
News
Next-gen Medical Devices?
Product stageSegments
Expansion
?
Implantable surgical devices
?

Catalyst OrthoScience is a medical device company focused on the upper extremity orthopedics market, developing innovative solutions for shoulder replacement surgery. Their flagship product, the Archer CSR Total Shoulder System, is a unique bone-preserving total shoulder arthroplasty system featuring a precision elliptical humeral head and less invasive glenoid component. The patented instrumentation is designed for consistent anatomic joint line restoration and glenoid insertion, offering precision and accuracy in shoulder restoration while preserving the patient's bone and soft tissue.

In addition to the Archer CSR Total Shoulder System, Catalyst offers the Archer R1 Reverse Shoulder System, a single-tray arthroplasty system engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. Providing surgeon-targeted implant positioning, a streamlined and versatile system, and bone-sparing implants, the Archer R1 Reverse Shoulder System received FDA 510(k) clearance in 2021.

Catalyst also received FDA 510(k) clearance in February 2023 for its Stemmed CSR Total Shoulder Arthroplasty System with an ellipsoid anatomic head, the market's first stemmed arthroplasty system featuring an ellipsoid humeral head. This fully convertible system allows for more accurate restoration of natural joint kinematics compared to spherical head designs and can be converted to a reverse shoulder as needed. Internationally recognized orthopedic surgeon Theodore Blaine, MD, performed the first series of procedures with this system in May 2023.

Furthermore, Catalyst offers 3D Targeting Preoperative Shoulder Replacement Planning Software to support preoperative planning for shoulder arthroplasty. As of 2023, Catalyst is the only company offering anatomically shaped non-spherical heads in both stemmed and stemless shoulder replacement solutions.

In January 2022, Carl O'Connell was appointed as Catalyst's President and CEO, bringing extensive experience in orthopedics and executive leadership. Under O'Connell's leadership, Catalyst aims to maintain its market leadership by enhancing its product portfolio and focusing on sustainable growth.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
5867 Whisperwood Court Naples FL USA
Founded year:
2014
Employees:
11-50
IPO status:
Private
Total funding:
USD 67.5 mn
Last Funding:
USD 20.0 mn (Series Unknown; Sep 2024)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.